APELLIS PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. – APLS

NEW ORLEANS, Aug. 25, 2023 /PRNewswire/ — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 2, 2023 to file lead plaintiff applications in a securities class action lawsuit against Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS), if they purchased the Company’s shares between January 28, 2021 and July 28, 2023, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Delaware.

Get Help

Apellis investors should visit us at https://claimsfiler.com/cases/nasdaq-apls/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

Apellis and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

On July 15, 2023, the American Society of Retina Specialists reported concerns with SYFOVRE, one of the Company’s leading therapeutic treatments for geographic atrophy, (a leading cause of blindness), based on physician reports of eye inflammation in patients treated with SYFOVRE, including six instances of occlusive retinal vasculitis, a type of inflammation that blocks blood flow through the vessels that feed the retina and that can potentially result in blindness. Then, on July 29, 2023, the Company disclosed the confirmation of a seventh event of retinal vasculitis resulting from the treatment, and also that it was evaluating an eighth reported event.

On this news, shares of Apellis fell $6.27 per share, or approximately 19.6%, from a close of $32.02 per share on July 28, 2023, to close at $25.75 per share on July 31, 2023.

The case is Soderberg v. Apellis Pharmaceuticals Inc., et al., No. 23-cv-00834.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

SOURCE ClaimsFiler

Originally published at https://www.prnewswire.com/news-releases/apellis-pharmaceuticals-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-apellis-pharmaceuticals-inc—apls-301910401.html
Images courtesy of https://pixabay.com

author avatar
RR Editor
reality tv gossipreality tv gossip
Search Engine Optimization (SEO)

Hot Topics

Related Articles